Search research articles
Contact Us
Filters
Showing results (61-70 of 129) with videos related to
Page
of 13
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
September 4, 2025
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy
Andres Chang, Adam N Pelletier, Donald J McGuire, et al.
Blood Advances
|
October 18, 2021
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Alessia Castellino, Yucai Wang, Melissa C Larson, et al.
The Lancet. Oncology
|
July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes, Armando Santoro, Margaret Shipp, et al.
Blood Advances
|
April 26, 2024
Defining primary refractory large B-cell lymphoma
Allison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood
|
September 27, 2021
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Mazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, et al.
Blood Advances
|
August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Cancers
|
March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
Walter Hanel, Polina Shindiapina, David A Bond, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
British Journal of Haematology
|
December 22, 2017
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
Nirav N Shah, Aniko Szabo, Scott F Huntington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 129) with videos related to
Sort By:
Page
of 13
Proceedings of the National Academy of Sciences of the United States of America
|
September 4, 2025
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy
Andres Chang, Adam N Pelletier, Donald J McGuire, et al.
Blood Advances
|
October 18, 2021
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Alessia Castellino, Yucai Wang, Melissa C Larson, et al.
The Lancet. Oncology
|
July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes, Armando Santoro, Margaret Shipp, et al.
Blood Advances
|
April 26, 2024
Defining primary refractory large B-cell lymphoma
Allison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood
|
September 27, 2021
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Mazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, et al.
Blood Advances
|
August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Cancers
|
March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
Walter Hanel, Polina Shindiapina, David A Bond, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
British Journal of Haematology
|
December 22, 2017
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
Nirav N Shah, Aniko Szabo, Scott F Huntington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Page
of 13